Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cancer Selective Target Degradation by Folate-Caged PROTACs

Journal of the American Chemical Society(2021)10.1021/jacs.1c00451Source: DataRank Database

Cancer Selective Target Degradation by Folate-Caged PROTACs is a research paper published in Journal of the American Chemical Society (2021). On theSindex it has a DataRank of 8.4. It has been cited 292 times, with 200 citing works in its 1-hop citation network.

N/A

8.4DataRank · unranked

Scored on demand from live citation data

Open Access292 citations · 200 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 13.68)OA: greenTopics (54)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 10%Citation Network 90%

Base Score Contribution

0.852

From this paper's citation signal

Citation Network Contribution

7.6

From 200 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 200 citers.

Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs)
Expert Opinion on Drug Discovery202339 citations22 referencesContributes 0.168
Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction
European Journal of Medicinal Chemistry202326 citations22 referencesContributes 0.150
Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach
Journal of the American Chemical Society202380 citations31 referencesContributes 0.142
Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
Angewandte Chemie International Edition2021289 citations41 referencesContributes 0.138
Design, Synthesis, and Evaluation of Trivalent PROTACs Having a Functionalization Site with Controlled Orientation
Bioconjugate Chemistry202125 citations25 referencesContributes 0.130

Authors (8)

He Chen ORCID,Yi Liu ORCID,Yudao Shen,Fanye Meng,H. Ümit Kanıskan ORCID

Live enrichment

PubMed:33970635 PMC:PMC8219215 OpenAlex:https://openalex.org/W3163700030

National Cancer Institute

Grant: P30CA196521

National Cancer Institute

Grant: R01CA218600

National Cancer Institute

Grant: R01CA230854

National Cancer Institute

Grant: R01CA260666

National Cancer Institute

Grant: R35CA253027

National Institute of General Medical Sciences

Grant: R01GM122749

NCI NIH HHS

Grant: R01 CA200573

NIH HHS

Grant: S10 OD025132

NCI NIH HHS

Grant: R01 CA200651

NCI NIH HHS

Grant: R01 CA177910

National Institutes of Health

Grant: 5R01CA260666-05

Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias

National Institutes of Health

Grant: 3R01CA230854-03S1

(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer

National Institutes of Health

Grant: 1P30CA196521-01

Mouse Genetics

National Institutes of Health

Grant: 5R01CA218600-05

Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias

National Institutes of Health

Grant: 5R01GM122749-03

Discovery of Selective Inhibitors for Histone Methyltransferases

National Institutes of Health

Grant: 1S10OD025132-01A1

An AVANCE NEO 600 MHz NMR Spectrometer System for Structural and Chemical Biology

National Institutes of Health

Grant: 5R35CA253027-02

Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies

FWCI

13.68

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: STM Policy #29

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8219215

publisherhttps://pubs.acs.org/doi/pdf/10.1021/jacs.1c00451

journalhttps://doi.org/10.1021/jacs.1c00451

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33970635

Fields of Study

Protein Degradation and InhibitorsUbiquitin and proteasome pathwaysPeptidase Inhibition and Analysis0301 basic medicine03 medical and health sciencesAntineoplastic AgentsEnzyme InhibitorsFolic AcidHumansLigandsMolecular StructureNeoplasmsProteolysisPyrrolidinesThiazolesUbiquitin-Protein Ligases

MeSH Terms

Antineoplastic AgentsEnzyme InhibitorsFolic AcidHumansLigandsNeoplasmsPyrrolidinesThiazolesMolecular StructureUbiquitin-Protein LigasesProteolysis

Keywords

ChemistryUbiquitin ligaseProtein degradationProteasomeUbiquitinProteolysisCancer cellFolate receptorCancerCancer researchCell biologyPharmacologyBiochemistryBiologyEnzymeGeneticsGenePyrrolidinesMolecular StructureUbiquitin-Protein LigasesAntineoplastic AgentsLigandsThiazolesFolic AcidNeoplasmsHumansEnzyme Inhibitors

Sustainable Development Goals

SDG 3: 3. Good health